Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2015 1
2020 2
2021 10
2022 11
2023 6
2024 7
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Receptor tyrosine kinase inhibitors in cancer.
Ebrahimi N, Fardi E, Ghaderi H, Palizdar S, Khorram R, Vafadar R, Ghanaatian M, Rezaei-Tazangi F, Baziyar P, Ahmadi A, Hamblin MR, Aref AR. Ebrahimi N, et al. Cell Mol Life Sci. 2023 Mar 22;80(4):104. doi: 10.1007/s00018-023-04729-4. Cell Mol Life Sci. 2023. PMID: 36947256 Free PMC article. Review.
Oncolytic virotherapy: Challenges and solutions.
Goradel NH, Baker AT, Arashkia A, Ebrahimi N, Ghorghanlu S, Negahdari B. Goradel NH, et al. Among authors: ebrahimi n. Curr Probl Cancer. 2021 Feb;45(1):100639. doi: 10.1016/j.currproblcancer.2020.100639. Epub 2020 Aug 15. Curr Probl Cancer. 2021. PMID: 32828575 Review.
Emerging immunologic approaches as cancer anti-angiogenic therapies.
Azimi M, Manavi MS, Afshinpour M, Khorram R, Vafadar R, Rezaei-Tazangi F, Arabzadeh D, Arabzadeh S, Ebrahimi N, Aref AR. Azimi M, et al. Among authors: ebrahimi n. Clin Transl Oncol. 2025 Apr;27(4):1406-1425. doi: 10.1007/s12094-024-03667-2. Epub 2024 Sep 18. Clin Transl Oncol. 2025. PMID: 39294514 Review.
Breaking the barriers: Overcoming cancer resistance by targeting the NLRP3 inflammasome.
Pazhouhesh Far N, Hajiheidari Varnousafaderani M, Faghihkhorasani F, Etemad S, Abdulwahid ARR, Bakhtiarinia N, Mousaei A, Dortaj E, Karimi S, Ebrahimi N, Aref AR. Pazhouhesh Far N, et al. Among authors: ebrahimi n. Br J Pharmacol. 2025 Jan;182(1):3-25. doi: 10.1111/bph.17352. Epub 2024 Oct 12. Br J Pharmacol. 2025. PMID: 39394867 Review.
The emerging role of regulatory cell-based therapy in autoimmune disease.
Ghobadinezhad F, Ebrahimi N, Mozaffari F, Moradi N, Beiranvand S, Pournazari M, Rezaei-Tazangi F, Khorram R, Afshinpour M, Robino RA, Aref AR, Ferreira LMR. Ghobadinezhad F, et al. Among authors: ebrahimi n. Front Immunol. 2022 Dec 14;13:1075813. doi: 10.3389/fimmu.2022.1075813. eCollection 2022. Front Immunol. 2022. PMID: 36591309 Free PMC article. Review.
Role of the Wnt and GTPase pathways in breast cancer tumorigenesis and treatment.
Ebrahimi N, Kharazmi K, Ghanaatian M, Miraghel SA, Amiri Y, Seyedebrahimi SS, Mobarak H, Yazdani E, Parkhideh S, Hamblin MR, Aref AR. Ebrahimi N, et al. Cytokine Growth Factor Rev. 2022 Oct;67:11-24. doi: 10.1016/j.cytogfr.2022.05.001. Epub 2022 May 5. Cytokine Growth Factor Rev. 2022. PMID: 35934612 Review.
33 results